Global Tech Reporter
SEE OTHER BRANDS

Get your daily news on science and technology

Global Tech Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Tech Reporter.

Press releases published on April 30, 2025

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by …

Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast

Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast

L’ensemble des résultats des parties d’escalade et d’expansion de dose de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) après chimiothérapie d’induction chez des patients atteints d’un cancer du pancréas localement avancé ou à la limite de la résécabilité …

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025 New gene expression signature for cancer patients to predict clinical response to immune checkpoint. Potential of signature to enhance …

Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard  - Au congrès annuel de l’AACR 2025

Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard - Au congrès annuel de l’AACR 2025

Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard Au congrès annuel de l’AACR 2025 Une nouvelle signature d’expression génique pour prédire la réponse clinique aux points de contrôle immunitaires …

Nicox Provides Full Year 2024 Financial Results

Nicox Provides Full Year 2024 Financial Results

Nicox SA revenue of €7.9 million for full year 2024  Exceptional income of €13.7 million following the transfer of VYZULTA’s future revenue stream to Soleus Capital Nicox SA cash of €10.5 million on 31 December 2024 and the Company estimates it is …

Nicox : Résultats financiers de l’année 2024

Nicox : Résultats financiers de l’année 2024

Chiffre d’affaires de Nicox SA de 7,9 millions d’euros pour l’année 2024  Produits exceptionnels de 13,7 millions d’euros suite à la cession du flux futur de redevances de VYZULTA au fond Soleus Capital Trésorerie de Nicox SA au 31 décembre 2024 de 10,5 …

Port Access Approval Received as Last Key Item for FID at Minim Martap Bauxite Project

Port Access Approval Received as Last Key Item for FID at Minim Martap Bauxite Project

Highlights: With port access approval in place, detailed design for bauxite port loading infrastructure has now commenced Final tenders received for mine development and road access upgrade to Inland Rail Facility (IRF) Engineering design of IRF …

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for …

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million  up by 3% in constant currencies (cc); stable in USD up by 5%[1] at a comparable growth rate (CGR), when adjusted for impact of …

ArcelorMittal S.A.: ArcelorMittal reports first quarter 2025

ArcelorMittal S.A.: ArcelorMittal reports first quarter 2025

Luxembourg, April 30, 2025 - ArcelorMittal (referred to as “ArcelorMittal” or the “Company” or the "Group") (MT (New York, Amsterdam, Paris, Luxembourg), MTS (Madrid)), the world’s leading integrated steel and mining company, today announced results1 for …

Nexans - Q1 2025, promising start to the year

Nexans - Q1 2025, promising start to the year

First-quarter 2025 financial information Promising start to 2025 Electrification segment, a key driver of our growth, delivering +6.8% organic growth in Q1 2025 No material impact from “US Liberation Day” Tariff 2025 guidance confirmed First-quarter 2025 …

Nexans - T1 2025, un début d'année prometteur

Nexans - T1 2025, un début d'année prometteur

Information financière du premier trimestre 2025 Un début d’année prometteur pour 2025 Segment Électrification : un moteur clé de notre croissance, avec +6,8 % de croissance organique au T1 2025 Aucun impact significatif lié au tarif du “US Liberation Day” …

Equinor to commence second tranche of the 2025 share buy-back programme

Equinor to commence second tranche of the 2025 share buy-back programme

Equinor (OSE: EQNR, NYSE: EQNR) will after the annual general meeting 14 May 2025 commence the second tranche of up to USD 1,265 million of the share buy-back programme for 2025, as announced in relation with the first quarter results 30 April 2025. …

Equinor vil starte andre transje av tilbakekjøpsprogrammet for aksjer for 2025

Equinor vil starte andre transje av tilbakekjøpsprogrammet for aksjer for 2025

Equinor (OSE: EQNR, NYSE: EQNR) vil etter generalforsamlingen 14. mai 2025 starte andre transje av tilbakekjøpsprogrammet for aksjer for 2025 på inntil 1.265 millioner USD, som annonsert i forbindelse med selskapets første kvartalsresultat 30. april 2025. …

Equinor ASA: Key information relating to cash dividend for first quarter 2025

Equinor ASA: Key information relating to cash dividend for first quarter 2025

Key information relating to the cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for first quarter 2025. Cash dividend amount: 0.37 Announced currency: USD Last day including rights: 15 August 2025 Ex-date Oslo Børs : 18 August 2025 Ex-date New …

Equinor ASA: Nøkkelinformasjon angående kontantutbytte for første kvartal 2025

Equinor ASA: Nøkkelinformasjon angående kontantutbytte for første kvartal 2025

Nøkkelinformasjon angående kontantutbytte for Equinor (OSE: EQNR, NYSE: EQNR) for første kvartal 2025. Utbyttebeløp: 0,37 Annonsert valuta: USD Siste dag inklusive: 15. august 2025 Ex-dato Oslo Børs: 18. august 2025 Ex-dato New York Stock Exchange: 19. …

Equinor first quarter 2025 results

Equinor first quarter 2025 results

Equinor (OSE:EQNR, NYSE:EQNR) delivered adjusted operating income* of USD 8.65 billion and USD 2.25 billion after tax in the first quarter of 2025. Equinor reported net operating income of USD 8.87 billion and net income at USD 2.63 billion. Adjusted net …

Equinors resultater for første kvartal 2025

Equinors resultater for første kvartal 2025

Equinor (OSE:EQNR, NYSE:EQNR) leverte et justert driftsresultat* på 8,65 milliarder USD og 2,25 milliarder USD etter skatt i første kvartal 2025. Det rapporterte driftsresultatet var 8,87 milliarder USD, og resultatet for perioden var 2,63 milliarder USD. …

The 8th Digital China Summit opened in Fuzhou, Fujian

The 8th Digital China Summit opened in Fuzhou, Fujian

FUZHOU, China, April 29, 2025 (GLOBE NEWSWIRE) -- On April 29, the 8th Digital China Summit (DCS) opened in Fuzhou, Fujian province. The event is co-hosted by the National Development and Reform Commission, the National Data Administration, the Cyberspace …

Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel

Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service